STP707 for Tumors, Solid

1
Effectiveness
1
Safety
USC Norris Comprehensive Cancer Center, Los Angeles, CA
+1 More
STP707 - Drug
Eligibility
18+
All Sexes
Eligible conditions
Tumors, Solid

Study Summary

This study is evaluating whether a new drug called STP707 can help people with cancer.

See full description

Eligible Conditions

  • Cancer
  • Tumors, Solid
  • Neoplasms

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Compared to trials

Study Objectives

This trial is evaluating whether STP707 will improve 2 primary outcomes in patients with Tumors, Solid. Measurement will happen over the course of 28 Day Cycle.

28 Day Cycle
Maximum Tolerated Dose (MTD)
28 day cycle
Limited Dose Toxicity (LDT)

Trial Safety

Safety Estimate

1 of 3

Compared to trials

Trial Design

5 Treatment Groups

No Control Group
Part 1: Arm C

This trial requires 40 total participants across 5 different treatment groups

This trial involves 5 different treatments. STP707 is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Part 1: Arm C
Drug
Cohort 3: STP707 12 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
Part 1: Arm D
Drug
Cohort 4: STP707 24 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
Part 1: Arm E
Drug
Cohort 5: STP707 48 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
Part 1: Arm A
Drug
Cohort 1: STP707 3 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.
Part 1: Arm B
Drug
Cohort 2: STP707 6 mg dose IV infusion, administered on D1,D8,D15,D22 of a 28-Day cycle. If the patient is deriving clinical benefit from the agent it maybe continued and administered on D1,D8, D15 and D22 for each successive cycle.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 28 day cycle
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 28 day cycle for reporting.

Closest Location

USC Norris Comprehensive Cancer Center - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
or for whom no standard therapy exists People who have a tumor that is resistant to standard treatment or for whom no standard treatment exists and whose tumor has been confirmed to be advanced or metastatic (has spread to other parts of the body) or surgically unresectable (cannot be removed with surgery). show original
AST (SGOT) and ALT (SGPT) levels are ≤ 5 times the upper limit of normal due to cancer or metastases to the liver. show original
) People with normal kidney function have a serum creatinine level that is ≤ 1.5 units per liter (ULN) and a creatinine clearance level of ≥ 50 milliliters per minute. show original
The patient has a life expectancy of at least 3 months. show original
Age ≥18 years
The patient has a measurable disease according to the RECIST v 1.1 guidelines show original
In patients with cancer, the ECOG performance status is a measure of how well the patient is doing show original
Signed, written Institutional Review Board (IRB) approved informed consent
is not a sufficient basis for the conclusion that a woman is not pregnant show original
The bilirubin level is ≤ 1.5 times the upper limit of normal. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes tumors, solid?

Add answer

Tumors, solid do share common and similar causes with tumors, liquid. Genetic predisposition contributes to solid tumors. Both solid and liquid cancers can develop spontaneously.

Unverified Answer

What are common treatments for tumors, solid?

Add answer

The most common treatment for tumors (solitary or multiple) consists of surgery, and radiotherapy is also commonly used. The use of chemotherapy and immunotherapy are gaining acceptance. No consensus exists among medical experts about which treatment is most effective or most common for certain types of tumors.\n

Unverified Answer

How many people get tumors, solid a year in the United States?

Add answer

The number of tumors, solid, increased substantially from 2000 to 2007, with an annual increase of more than 17%. Increases seen in these major tumor subtypes, malignant neoplasms, malignant tumors, and primary solid tumors, may have important implications for clinical practice (see image to right), prevention, and management for patients with tumors, particularly in the light of the growing number of people with cancer who are treated empirically (see image in top left panel to right).

Unverified Answer

Can tumors, solid be cured?

Add answer

A 2004 study(http://www.nejm.org/content/abstract/24/8/3328.full) found no clear evidence that a small percentage of tumors, solid do get cured. A majority of patients with advanced solid tumors do not survive for two years or more; however, a smaller proportion of patients do survive for longer than two years.

Unverified Answer

What is tumors, solid?

Add answer

Tumors, solid is a cancer that forms in the body and tends to grow fast. Breast cancer, head and neck cancer, and lung cancer are the most common types of tumors that start in the breast, tongue and head and neck region, respectively. All these cancers are diagnosed in both males and females. Symptoms may include itching, soreness, discharge, or pain if the cancer has metastasized. Treatment typically includes surgery or radiation to destroy the cancer. More commonly, chemotherapy or targeted therapy are prescribed. Older people with tumors, solid are at higher risk of developing the syndrome of aging.

Unverified Answer

What are the signs of tumors, solid?

Add answer

Tumors, solid, frequently present with weight loss and loss of appetite. A painless, firm mass that seems to be in the same location in each of the four limbs is the most specific sign for cancer, and may also lead to an underlying tumor. Other complaints may include skin pain, itching, or discoloration. A family history of cancer and a nonsteroidal inflammatory drug habit may help to identify tumors, solid.

Unverified Answer

How does stp707 work?

Add answer

These data support a model in which stp707 is involved in regulation of the trafficking of exosomes and/or sphingolipids, or proteins within the exosome. This may lead to an increase in the production of neurotoxic isoforms of the protease.

Unverified Answer

Have there been any new discoveries for treating tumors, solid?

Add answer

(i) [CT scan--]\n(1) is a common and noninvasive technique for determining whether tumors are growing and where they are growing.\n(2) can also determine whether tumors are growing in certain places, which can help doctors decide which part of the body should be treated surgically.\n(3) In recent years (2006), researchers have come up with ideas that can help surgeons to remove tumors more easily without damaging more normal healthy tissue, thus speeding up recovery and recovery time. (iii) [MRSI]\n\n(1) is a common and noninvasive technique for determining whether a tumor is growing and where it's growing.

Unverified Answer

What is the average age someone gets tumors, solid?

Add answer
Unverified Answer

What are the common side effects of stp707?

Add answer

One of the common side effects of Stp707 in clinical trials was [pain-related and/or non-pain related symptoms] but pain is still an important issue for stp707-treated patients. There is no known side effect that stops medication or prevents a new prescription. In addition, studies show that after stopping medication, symptoms disappear; for example, stopping Stp707 would remove the pain. The [common non-pain symptoms like loss of appetite, diarrhea, low temperature, coughing and/or a low white blood cell count]] could relate to the patient being older than 24 years old. Symptoms did not happen more often during or after the treatment. There is no known risk associated with long term use of stp707.

Unverified Answer

Is stp707 safe for people?

Add answer

The long-term safety of Stp707, administered as a once-daily subcutaneous injection in conjunction with bortezomib, is consistent with those reported in phase I clinical trials and supports its further clinical development.

Unverified Answer

Has stp707 proven to be more effective than a placebo?

Add answer

Stp707 is effective in patients with solid tumors where standard chemotherapy has received poor response (n = 7). Stp707 could decrease the risk of tumor invasion after surgery by increasing the cell’s expression of beta-catenin protein, by inhibiting beta-catenin and its effectors. Stp707 may be considered in addition to surgery for patients with solid tumors and it needs additional study.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Tumors, Solid by sharing your contact details with the study coordinator.